Skip to main content

ACB · Aurora Cannabis Inc

Track ACB — free
$4.22 -0.04 (-0.96%)
Market Cap
$280.07M
Shares
65.74M
Volume · Nov 19 913.52K Avg daily vol (3M) 1.31M

Price & Indicators

 

Key stats

Close
$4.26
Open
$4.40
Day range
$4.26–4.43
52-week closing range
$2.58–5.57
Average volume, 30 days
1.5M
Short interest
8.4M · 12.8% of shares · 12.8 days
Short volume, last session
49%
Last earnings
Nov 12, 2026
Price history
Jan 2020 to Nov 2026

Up next

Feb 3, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 9
Current report 6-K
Special meeting scheduled for December 23, 2026

AURORA CANNABIS INC. will hold a virtual special meeting on December 23, 2026, with November 18, 2026 serving as the record date for notice, voting and beneficial ownership determination.

6 source passages
Subject: AURORA CANNABIS INC. Record Date for Notice of Meeting : November 18, 2026 Record Date for Voting (if applicable) : November 18, 2026 Beneficial Ownership Determination Date : November 18, 2026 Meeting Date : December 23, 2026 Meeting Location (if available) : Virtually Meeting Open the document at this passage
Nov 5
Current report 6-K
Organigram to acquire Aurora in cash-and-share deal

Organigram Global Inc. will acquire all issued and outstanding Aurora Cannabis Inc. shares for C$7.80 cash, 5.8626 Organigram shares, or C$3.75 cash plus 3.0431 shares, subject to proration. The transaction is expected to close in January 2027.

2 source passages
Aurora has cancelled its investor call, originally scheduled for November 12, 2026, at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time, due to the Company’s announcement on November 3, 2026, that Aurora has entered into a definitive agreement (the “Arrangement Agreement”) with Organigram Global Inc. (“Organigram”) pursuant to which Organigram will acquire all of the issued and outstanding common shares of Aurora (the “Aurora Shares”). Pursuant to the terms of the Arrangement Agreement, Organigram will acquire each of the issued and outstanding Aurora Shares in exchange for either (i) C$7.80 in cash, (ii) 5.8626 common shares in the capital of Organigram (the “Organigram Shares”), or (iii) a combination of C$3.75 in cash and 3.0431 Organigram Shares, subject to proration, structured as a statutory plan of arrangement pursuant to the Business Corporations Act (British Columbia) (the “Transaction”). The Transaction is expected to be completed in January 2027, subject to shareholder, court and regulatory approvals, and other customary closing conditions. Open the document at this passage
Nov 5
Current report 6-K
Revenue rises while net loss narrows

Aurora Cannabis Inc. reported net revenue of 86,021 versus 78,809 and net loss of 21,050 versus 53,049 for the three months ended September 30, 2026 and 2025, in thousands of Canadian dollars.

Read from the first part of this long document
6 source passages
AURORA CANNABIS INC. ($ thousands) Three months ended September 30, 2026 | 2025(1) Net revenue | 12 | 86,021 | 78,809 | 153,575 | 152,885 Net loss | | (21,050) | (53,049) | (25,083) | (72,914) Open the document at this passage
Nov 4
Current report 6-K
Organigram agrees to acquire cannabis company for C$7.80 per share

Organigram Global Inc. agreed to acquire Aurora Cannabis Inc. for C$7.80 in total consideration per share, valuing Aurora at approximately C$561 million; Aurora shareholders are expected to hold approximately 35% of Organigram’s economic interest and 42% of its voting interest.

Read from the first part of this long document
3 source passages
On November 3, 2026, Aurora and Organigram Global Inc. (“Organigram”) announced that they entered into an arrangement agreement dated November 2, 2026 (the “Arrangement Agreement”) pursuant to which Organigram agreed to acquire all of the issued and outstanding common shares of Aurora (“Aurora Shares”) pursuant to a court-approved plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”). holders of Aurora Shares (“Aurora Shareholders”) (other than dissenting Aurora Shareholders) will receive C$7.80 in total consideration per Aurora Share The Arrangement values Aurora at approximately C$561 million on a fully diluted equity value basis. Aurora Shareholders are expected to hold approximately 35% of the economic interest and 42% of the voting interest in Organigram, on a fully diluted basis, following the completion of the Arrangement. Open the document at this passage
Nov 3
Current report 6-K
Acquisition agreed at C$7.80 per share with 93% premium

Aurora Cannabis Inc. agreed to sell all outstanding shares to Organigram for C$7.80 per share, valuing the company at approximately C$561 million on a fully diluted basis and representing a 93% premium; completion is expected in January 2027.

3 source passages
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a price of C$7.80 per Aurora Common Share (the “Transaction”). The Transaction values Aurora at approximately C$561 million on a fully diluted equity value basis. The consideration represents a 93% premium to the unaffected closing share price of Aurora Shares on the TSX as of August 10, 2026, the last full trading day of Aurora prior to the announcement by Curaleaf Holdings, Inc. (“Curaleaf”) of its intention to launch a hostile takeover bid for Aurora (the “Unaffected Price”), and a 21% premium relative to the current bid value of the Curaleaf hostile offer^3^ (the “Hostile Bid”) as most recently amended on October 6, 2026, which was unanimously rejected by Aurora’s Board of Directors. Subject to the satisfaction of such conditions, the Transaction is expected to be completed in January 2027. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+11.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.1%
Year over year · more shares
Price change (1Y)
-0.9%
Trailing year
Short interest
12.8%
Latest settlement · 12.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +19%
above
Price vs 50-day avg −1%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 56%
mid-range
Momentum
relative strength
Very Strong
1-month return +7%
trailing
6-month return +17%
trailing
YTD return +1%
this year
Relative strength +23%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.81% of shares out · ▲ +2.7% MoM · 12.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
160 holders — mid 3-yr range
Squeeze score 83
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −54%
past year
ATR 4.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Dec 31, 2021
by the first half of fiscal 2023
Annualized cost savings $150M – $170M
annualized basis
Cost savings $150M – $170M
Previous outlook earlier release · from the Earnings Call filed Sep 30, 2021

Still-open targets the latest release did not restate under the same label.

Quarterly SG&A run rate · by the time we exit this fiscal year up to $40M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+19% Bullish
Price vs 50-day avg
−1% Neutral
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
56% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.81% of shares out · ▲ +2.7% MoM · 12.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
160 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $4 · 56% Range high $6
vs 200-day avg +19% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACB
Aurora Cannabis Inc
this stock
$280.07M +0.9% — — 12.8%
TAK
Takeda Pharmaceutical Co Ltd
$68.40B +37.3% — — 0.1%
GALDY
Galderma Group AG
$50.89B +5.3% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$44.97B +23.5% +4.3% 87.6 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
160
% held
11.5%
Net QoQ
+2.3M sh
Top holder
K2 PRINCIPAL FUND, L.P.
Held Float
View
Held by Funds
Fund positions
17
View
Short & Settlement
Short Interest Rising
Shares short
8.4M
Days to cover
12.8d
Change
+223.1K sh
View
Short Volume
Short vol %
49%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
6.5K
Value
$26.7K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
36.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 9, 2026
This year
48

AURORA CANNABIS INC. will hold a virtual special meeting on December 23, 2026, with November 18, 2026 serving as the record date for notice, voting and beneficial ownership determination.

View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
ACB -14.6% +7.3% +17.0% +4.9% +1.0%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -9.2% +13.6% +22.7% +10.2% -4.0%
Key facts CIK 1683541 CUSIP 05156X850 13F (30d) 204 filings 142 filers Visit website